A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial DOI Creative Commons
Jonathan Cook, Piers Patten, Nicholas Peckham

et al.

The Lancet Haematology, Journal Year: 2025, Volume and Issue: 12(4), P. e294 - e303

Published: April 1, 2025

Language: Английский

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial DOI Creative Commons
Jonathan Cook, Piers Patten, Nicholas Peckham

et al.

The Lancet Haematology, Journal Year: 2025, Volume and Issue: 12(4), P. e294 - e303

Published: April 1, 2025

Language: Английский

Citations

1